Key hallmark of ALS is successfully reversed in laboratory
Scientists demonstrated how to reverse the incorrect localisation of three RNA-binding proteins in ALS, potentially leading to treatments.
List view / Grid view
Scientists demonstrated how to reverse the incorrect localisation of three RNA-binding proteins in ALS, potentially leading to treatments.
Scientists have used genetic sequencing to demonstrate how the transmission of gut bacteria influences its evolution and functions, which could effect human health.
Fenofibrate and its active form, fenofibric acid, have been shown to significantly reduce COVID-19 infection in human cells.
Researchers have been using artificial intelligence to study how the microbiome interacts with the human system to improve vaccine response.
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
Eran Blacher has won the NOSTER & Science Microbiome Prize for discovering the link between the microbiome and neurodegenerative diseases.
Scientists have shown that start codon disruption with CRISPR-Cas9 gene editing can prevent Fuchs’ corneal dystrophy in mouse models.
NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
Researchers used an experimental small molecule that helped restore the removal of damaged mitochondria from brain cells in a mouse model of Parkinson's.
A novel synthetic “switch” has been developed that could hold the key to revolutionary smart insulin therapy for diabetic patients.
Scientists from the University of Chicago discovered that the drug masitinib inhibits the replication of SARS-CoV-2 in mice.
New research found mutations that cause melanoma result from a chemical conversion in DNA fuelled by sunlight, undermining previous theories.
Research shows that cells gather more data inside the thalamus than once believed, potentially changing medicines for brain disorders.
Scientists have uncovered the crucial role of the enzyme NMNAT-2 in ovarian cancers, as well as other biomarkers that could lead to treatments.
Researchers have used comparative metabologenomics to uncover what may be “silencing” bacteria to produce desirable compounds.